Pancreatic Cancer Research

ResearcherChinese University of Hong KongActive in the last 2 years

Juan Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7338-7942; OpenAlex author ID A5100390041. Sources: OpenAlex.

Their work

Papers
2 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 2

  1. 20(S)-Ginsenoside Rh2 overcomes gemcitabine resistance in pancreatic cancer by inhibiting LAMC2-Modulated ABC transporters. First author DOI 10.1016/j.jare.2024.09.006↗
  2. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway. Co-author DOI 10.1186/s13046-022-02270-z↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hong‐Xi Xu · 2 shared papers, 2022–2025 · strength 0.44
  2. Yan‐Fang Xian · 2 shared papers, 2022–2025 · strength 0.44
  3. Zhi‐Xiu Lin · 2 shared papers, 2022–2025 · strength 0.44
  4. William Chi Shing Cho · 2 shared papers, 2022–2025 · strength 0.44
  5. Yulin Wu · 1 shared paper, 2025 · strength 0.28
  6. Yang Li · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.